Physiological functions of keratinocyte epidermal growth factor receptors and their role in the development of skin toxicity during targeted cancer therapy

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The binding of epidermal growth factor (EGFR) receptors is a good target for the treatment of lung, colon, pancreatic, head and neck cancers. The adverse events that develop as a result of therapy, in the form of lesions of the skin and mucous membranes, is a serious problem for the doctor to choose a long-term treatment strategy. The developing symptoms of skin toxicity, as skin problems in patients are often called, are worrisome and often affect the quality of life and compliance with the treatment regimen. Thus, it is important for doctors to know the prerequisites and ways to manage skin toxicity associated with the use of tyrosine kinase receptor inhibitors of epidermal growth factor.

The mechanism and consequences of EGF receptor activation are described to explain the development of undesirable skin toxicity associated with inhibition of the epidermal growth factor receptor.

Full Text

Restricted Access

About the authors

Ekaterina V. Orlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: orlovaderm@yandex.ru
ORCID iD: 0000-0002-1684-8781
SPIN-code: 6332-3970
Scopus Author ID: 57210471902
ResearcherId: AAG-7087-2021

PhD, assoc professor, department of dermatology and venerology 

Russian Federation, 8 buil. 2 Trubetskaya street, 119991 Moscow

References

  1. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48(1):193–216. doi: 10.1146/annurev.bi.48.070179.001205
  2. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1 Suppl 4):27–36. doi: 10.1053/sonc.2002.31525
  3. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 1991;9(5):553–562. doi: 10.3109/07357909109018953
  4. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer. 1997;70(6):722–726. doi: 10.1002/(sici)1097-0215(19970317)70:6<722::aid-ijc15>3.0.co;2-b
  5. Ethier SP. Signal transduction pathways: the molecular basis for targeted therapies. Semin Radiat Oncol. 2002;12(3 Suppl 2):3–10. doi: 10.1053/srao.2002.34863
  6. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32(12):2070–2074. doi: 10.1016/s0959-8049(96)00243-2
  7. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993;13(4):1133–1137.
  8. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in nonsmall cell lung cancer to long term survival. Br J Cancer. 1993;68:162–165. doi: 10.1038/bjc.1993.306
  9. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998;77(4):663–669. doi: 10.1038/bjc.1998.106
  10. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218(3):460–466. doi: 10.1002/jcp.21635
  11. Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71(1):1–20. doi: 10.1006/geno.2000.6341
  12. Ceresa BP, Peterson JL. Cell and molecular biology of epidermal growth factor receptor. Int Rev Cell Mol Biol. 2014;313:145–178. doi: 10.1016/B978-0-12-800177-6.00005-0
  13. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–298. doi: 10.1093/jjco/hyv207
  14. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164(5):769–779. doi: 10.1083/jcb.200307137
  15. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29:1(Suppl 4):3–14. doi: 10.1053/sonc.2002.31520
  16. Wang YN, Hung MC. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci. 2012;2(1):13. doi: 10.1186/2045-3701-2-13
  17. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and Other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 1999;68(1):965–1014. doi: 10.1146/annurev.biochem.68.1.965
  18. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–133. doi: 10.1091/mbc.4.1.121
  19. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of so. Am J Pathol. 1997;151(6):1523–1530.
  20. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21–26. doi: 10.1016/j.ijrobp.2003.11.041
  21. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301–311. doi: 10.1016/j.ccr.2005.03.003
  22. Johns TG, Mellman I, Cartwright GA, et al. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J. 2005;19(7):780–782. doi: 10.1096/fj.04-1766fje
  23. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non–small-cell lung cancer. J Clin Oncol. 2005;23(14):3235–3242. doi: 10.1200/JCO.2005.08.409
  24. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–1176. doi: 10.1046/j.1365-2133.2001.04226.x
  25. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151(1):238–241. doi: 10.1111/j.1365-2133.2004.06026.x
  26. Jatoi A, Green EM, Rowland KM, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–123. doi: 10.1159/000229751
  27. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–765. doi: 10.1634/theoncologist.12-7-756
  28. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147(3):598–601. doi: 10.1046/j.1365-2133.2002.04864.x
  29. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol. 2002;138(1):129–131. doi: 10.1001/archderm.138.1.129
  30. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107–119. doi: 10.1007/s11523-009-0114-0
  31. Dainichi T, Tanaka M, Tsuruta N, et al. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology. 2003;207(3):324–325. doi: 10.1159/000073100
  32. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84(1):23–26. doi: 10.1080/00015550310005898
  33. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol. 2010;24(8):958–960. doi: 10.1111/j.1468-3083.2009.03516.x
  34. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003;42(4):345–346. doi: 10.1080/02841860310006038
  35. Pascual JC, Bañuls J, Belinchon I, et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151(5):1111–1112. doi: 10.1111/j.1365-2133.2004.06265.x
  36. Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007;23(1):42–45. doi: 10.1111/j.1600-0781.2007.00273.x.

Statistics

Views

Abstract: 34

PDF (Russian): 1

Dimensions

Article Metrics

Metrics Loading ...

PlumX


Copyright (c) 2021 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies